Cargando…
First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China
BACKGROUND: Nonacog alfa (recombinant factor IX [FIX]) is approved in China for the control and prevention of bleeding events in patients with hemophilia B. This was the first study to assess prophylaxis and on-demand therapy with recombinant FIX replacement in a real-world setting in China. This st...
Autores principales: | Yang, Renchi, Wu, Runhui, Sun, Jing, Sun, Feifei, Rupon, Jeremy, Huard, Francois, Korth-Bradley, Joan M., Xu, Lihong, Luo, Binyu, Liu, Yingxue Cathy, Rendo, Pablo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154445/ https://www.ncbi.nlm.nih.gov/pubmed/34032739 http://dx.doi.org/10.1097/MD.0000000000026077 |
Ejemplares similares
-
Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies
por: Yang, Renchi, et al.
Publicado: (2020) -
Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF‐CC) in Subjects With Severe Hemophilia A
por: Korth‐Bradley, Joan, et al.
Publicado: (2018) -
The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program
por: Owaidah, Tarek, et al.
Publicado: (2017) -
Hemorrhagic pericardial effusion as the debut of acquired hemophilia in a chronic lymphocytic leukemia patient: A case report, and a review of acquired hemophilia A-related hematological malignancies
por: Bastida, José María, et al.
Publicado: (2017) -
Macroscopic hematuria as a risk factor for hypertension in ageing people with hemophilia and a family history of hypertension
por: Qvigstad, Christian, et al.
Publicado: (2020)